Related Experiment Video

Updated: Dec 8, 2025

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

15.0K

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications

Carlo Messina1, Carlo Cattrini2,3, Davide Soldato2,4

  • 1Department of Medical Oncology, Santa Chiara Hospital, 38122 Trento, Italy.

Journal of Oncology
|September 23, 2020
PubMed

Insights

Germline DNA damage repair (DDR) defects, particularly BRCA mutations, impact metastatic castration-resistant prostate cancer (mCRPC) outcomes. These mutations predict response to PARP inhibitors but raise concerns regarding genetic testing implications.

Area of Science:

  • Oncology
  • Genetics
  • Medical Research

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) has poor outcomes despite current therapies.
  • DNA damage repair (DDR) defects, including BRCA mutations, are prevalent in mCRPC.
  • BRCA mutations are linked to adverse tumor features and poor prognosis in mCRPC.

Purpose of the Study:

  • To review the prognostic and predictive roles of BRCA mutations in prostate cancer.
  • To discuss the clinical implications of BRCA mutations in mCRPC.
  • To explore the utility of mutational testing for prostate cancer patients.

Main Methods:

  • Comprehensive literature review.
  • Analysis of studies on BRCA mutations in prostate cancer.
  • Evaluation of prognostic and predictive data.

Main Results:

  • BRCA mutations are associated with poor outcomes in mCRPC.
  • BRCA mutations predict a favorable response to poly-ADP ribose polymerase (PARP) inhibitors.
  • Concerns exist regarding the implications of widespread genetic testing for patients and families.

Conclusions:

  • BRCA mutations have significant prognostic and predictive value in prostate cancer.
  • PARP inhibitors offer a targeted therapy option for mCRPC patients with BRCA mutations.
  • Further consideration is needed for the ethical and clinical aspects of genetic testing in prostate cancer.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.1K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.5K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.7K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
558
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K